Welcome to our dedicated page for Cutera news (Ticker: CUTR), a resource for investors and traders seeking the latest updates and insights on Cutera stock.
Cutera, Inc. (symbol: CUTR) is a leading innovator in the field of medical aesthetics, specializing in the design, development, manufacturing, marketing, and servicing of energy-based aesthetic systems. Established in 1998 by experienced laser and optical engineers in Brisbane, California, Cutera has grown to become a trusted authority in face and body energy-based medical aesthetic technologies.
Cutera pioneered Nd:YAG technology and has continued to innovate, offering a premium portfolio of products that include Xeo®, truSculpt®, and excel V™. In 2014, the company expanded its product line with two significant additions: excel HR™, which provides high-speed, comfortable hair removal, and enlighten™, the industry's first system combining picosecond and nanosecond wavelengths.
With a presence in over 40 countries and direct operations in North America, France, Australia, Japan, and Hong Kong, Cutera is committed to meeting the evolving needs of the medical aesthetic community. Their solutions are designed to deliver better results, faster and safer than ever before.
The company markets its products under various trademarks, including Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis Plus, Pico-genesis, Titan, truSculpt, and Xeo. Cutera derives the majority of its revenue from the United States but maintains a strong international presence.
Recent achievements include the introduction of innovative products that have set new industry standards. Cutera's focus on research and development ensures that they remain at the forefront of the medical aesthetic technology market, continuously providing advanced solutions to practitioners worldwide.
For the latest updates and relevant information about Cutera's performance, events, and developments, stay tuned to Cutera's news section on StockTitan.
Cutera, Inc. (NASDAQ: CUTR) announced participation in a fireside chat at the Stephens Annual Investment Conference. CEO Dave Mowry and VP Greg Barker will speak on November 16, 2022, at 4:00 pm CT in Nashville, TN. Interested parties can access the live webcast through the Investor Relations section of Cutera's website, with a replay available one hour after the event concludes.
Based in Brisbane, California, Cutera specializes in aesthetic and dermatology solutions, providing innovative products since 1998.
Cutera, Inc. (CUTR) will participate in a fireside chat at the Stifel Healthcare Conference on November 15, 2022, at 8:00 am ET. The event will feature CEO Dave Mowry and Executive Chairperson J. Daniel Plants, providing insights into the company's aesthetic and dermatology solutions. Attendees can access the live webcast via Cutera's Investor Relations page, with a replay available one hour post-event. Headquartered in Brisbane, California, Cutera has been a leader in innovative dermatological products since 1998.
Cutera, Inc. (NASDAQ: CUTR) announces the extensive launch of AviClear, the first FDA-cleared and Health Canada-approved device for treating acne. The product has gained significant traction since its FDA clearance in March 2022, receiving the 'Best Laser Treatment for Acne' award from Cosmopolitan Magazine. A new financing option is available for US consumers starting at $99/month. CEO Dave Mowry expressed confidence in growing patient demand, aiming to establish AviClear as the gold standard in acne treatment.
Cutera, Inc. (Nasdaq: CUTR) reported Q3 2022 revenue of $62.8 million, marking a 9% year-over-year increase. Capital equipment sales grew 27%, while consumable product revenue surged 66%. Despite a GAAP net loss of $12.1 million, the company reiterated its 2022 revenue guidance of $255 million to $260 million, driven by strong demand for its products and a full launch of AviClear in North America. The company faced foreign exchange headwinds of approximately $17 million but expects constant currency growth of 18-20% for the year.
Cutera, Inc. (CUTR) presented positive 12-month clinical data for AviClear at the Annual Fall Clinical Dermatology Conference held from October 20-23 in Las Vegas. The data indicates that after three treatment sessions, 92% of patients experienced visible improvement in acne after 12 months. Additionally, three-fourths of participants showed significant improvement, and two-thirds were assessed as clear or almost-clear. AviClear, the only FDA-cleared device for acne treatment, aims to provide an alternative to isotretinoin. The findings support the device's long-term effectiveness and safety.
Cutera, Inc. (CUTR) will announce its Q3 2022 financial results on November 3, 2022, after market close, followed by a conference call at 1:30 p.m. PT (4:30 p.m. ET). Interested parties can join the call by calling 1-800-319-4610 domestically or +1-631-891-4304 internationally, or via webcast on their website. Cutera specializes in aesthetic and dermatology solutions since 1998, providing innovative and effective treatment options worldwide.
Cutera, Inc. (CUTR) reports significant adoption of its AviClear laser treatment, with over 1,000 procedures performed since its launch in April 2022. This device is the first FDA-cleared option for treating all severities of acne. Recently, AviClear also gained approval from Health Canada. About 90% of patients showed visible improvement after treatment, scoring 4.9 out of 5 for satisfaction. CEO David Mowry noted unprecedented speed in physician adoption and patient interest, underscoring AviClear's impact in modern skincare.
Argo Group International Holdings, Ltd. announced the appointment of
Cutera, Inc. (Nasdaq: CUTR) reported second-quarter 2022 revenue of $64.2 million, reflecting a 10% year-over-year increase. This growth was supported by strong demand in capital equipment and consumables. Despite a GAAP net loss of $47.3 million and increased operating expenses of $45.1 million, the company maintains its 2022 revenue guidance of $255 million to $260 million. Key developments include the successful initial launch of its AviClear treatment for acne, with over 50 devices activated. The company anticipates adding more than 100 AviClear devices in Q3 2022.
Cutera, Inc. (NASDAQ: CUTR) will report its second-quarter financial results after market close on August 4, 2022. A conference call to discuss these results will follow at 1:15 p.m. PT (4:15 p.m. ET) on the same day. Investors can join the call by dialing 1-800-319-4610 domestically or +1-631-891-4304 internationally. The call will also be available via webcast through Cutera's Investor Relations page, with a replay available about one hour after the call concludes.
FAQ
What is the current stock price of Cutera (CUTR)?
What is the market cap of Cutera (CUTR)?
What does Cutera, Inc. specialize in?
When was Cutera, Inc. established?
What are some of Cutera’s key products?
Where is Cutera, Inc. headquartered?
In how many countries does Cutera have a presence?
What technology did Cutera pioneer?
Where does Cutera derive the majority of its revenue?
What is the significance of the product excel HR™?
What is unique about the enlighten™ system?
How does Cutera stay at the forefront of the industry?
